Why Don't We Have Proven Treatments for HFpEF?
- PMID: 28408453
- PMCID: PMC5407384
- DOI: 10.1161/CIRCRESAHA.116.310119
Why Don't We Have Proven Treatments for HFpEF?
Abstract
The lack of effective treatments for heart failure with preserved ejection fraction (HFpEF) represents a large and growing unmet need in cardiology today. A critical obstacle to therapeutic innovation in HFpEF has been the absence of animal models that accurately recapitulate the complexities of the human disease. Here we propose that more comprehensive multi-organ system and functional phenotyping of preclinical models is essential if we are to maximize our chances of discovering and validating novel targets for effective therapeutic development in HFpEF.
Keywords: aging; cardiology; exercise; heart failure; models, animal.
References
-
- Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. - PubMed
-
- Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15. - PubMed
-
- Horgan S, Watson C, Glezeva N, Baugh J. Murine models of diastolic dysfunction and heart failure with preserved ejection fraction. J Card Fail. 2014;20:984–95. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
